Authors: Fenner, H Rau, R

Citation: H. Fenner et R. Rau, Influence of gold versus methotrexate treatment on cytokine-profiles and markers of bone and cartilage destruction, Z RHEUMATOL, 60(3), 2001, pp. 174-176

Authors: Woodworth, TG Furst, DE Strand, V Kempeni, J Fenner, H Lau, CS Miller, F Day, R Lipani, J Brooks, P

Citation: Tg. Woodworth et al., Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: Towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies, J RHEUMATOL, 28(5), 2001, pp. 1163-1169

Authors: Rau, R Herborn, G Fenner, H

Citation: R. Rau et al., Links between joint damage and disability, RHEUMATOLOG, 39(12), 2000, pp. 1434-1435

Authors: Rau, R Herborn, G Zueger, S Fenner, H

Citation: R. Rau et al., The effect of HLA-DRB1 genes, rheumatoid factor, and treatment on radiographic disease progression in rheumatoid arthritis over 6 years, J RHEUMATOL, 27(11), 2000, pp. 2566-2575

Authors: Brooks, P Emery, P Evans, JF Fenner, H Hawkey, CJ Patrono, C Smolen, J Breeveld, F Day, R Dougados, M Ehrich, EW Gijon-Banos, J Kvien, TK Van Rijswijk, MH Warner, T Zeidler, H

Citation: P. Brooks et al., Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2, RHEUMATOLOG, 38(8), 1999, pp. 779-788